---
title: "Rexulti (brexpiprazole) in major depressive disorder: Safety questions"
description: "Safety questions on Rexulti (brexpiprazole) in major depressive disorder, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings and Side effects. Questions: Rexulti and suicidal thoughts: what are the risks and monitoring steps? What are the most common side effects of Rexulti for depression? How many patients stopped Rexulti for side effects in depression trials? Does Rexulti cause akathisia or restlessness in depression trials? 5 further questions follow. 9 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/safety"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rexulti (brexpiprazole) in major depressive disorder: Safety questions

Manufacturer: Otsuka America Pharmaceutical, Inc.; Lundbeck  
Prescribing information: [Rexulti](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf)

Safety questions that apply to every indication of Rexulti are on [Rexulti (brexpiprazole), all indications: Safety](https://www.evicenter.com/medical-information/rexulti/safety).

## Warnings

<a id="rexulti-suicidal-thoughts"></a>

### Rexulti and suicidal thoughts: what are the risks and monitoring steps?

> “In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant 
> classes) that included approximately 77,000 adult patients and over 4,400 pediatric patients, the incidence of 
> suicidal thoughts and behaviors in patients 24 years of age and younger was greater in antidepressant-treated 
> patients than in placebo-treated patients. The drug-placebo differences in the number of cases of suicidal 
> thoughts and behaviors per 1,000 patients treated are provided in Table 2. 
> No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number 
> was not sufficient to reach any conclusion about antidepressant drug effect on suicide. 
> Table 2 
> Risk Differences of the Number of Patients with Suicidal Thoughts or Behaviors in the 
> Pooled Placebo-Controlled Trials of Antidepressants in Pediatric* and Adult Patients 
> Age Range (years) 
> Drug-Placebo Difference in Number of Patients with Suicidal 
> Thoughts or Behaviors per 1,000 Patients Treated 
>
> Increases Compared to Placebo 
> <18 
> 14 additional patients 
> 18 to 24 
> 5 additional patients 
>
> Decreases Compared to Placebo 
> 25 to 64 
> 1 fewer patient 
> ≥65 
> 6 fewer patients 
> *REXULTI is not approved in pediatric patients with MDD. 
> It is unknown whether the risk of suicidal thoughts and behaviors in children, adolescents, and young adults 
> extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-
> controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression.  
> Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and 
> behaviors, especially during the initial few months of drug therapy and at times of dosage changes. Counsel 
> family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare 
> provider. Consider changing the therapeutic regimen, including possibly discontinuing REXULTI, in patients 
> whose depression is persistently worse or who are experiencing emergent suicidal thoughts or behaviors.”

Source: [REXULTI: Prescribing information, page 6, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=6)

<a id="rexulti-orthostatic-hypotension"></a>

### Can Rexulti cause dizziness or low blood pressure when standing?

> “Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest during initial 
> dose titration and when increasing the dose. In the short-term, placebo-controlled clinical studies of REXULTI 
> plus ADT in adult patients with MDD, the incidence of orthostatic hypotension-related adverse reactions in 
> REXULTI plus ADT-treated patients compared to placebo plus ADT-treated patients included: dizziness 
> (2% versus 2%) and orthostatic hypotension (0.1% versus 0%).”

Source: [REXULTI: Prescribing information, page 12, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=12)

> “Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, 
> patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with 
> known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or 
> conduction abnormalities), and patients with cerebrovascular disease. REXULTI has not been evaluated in 
> patients with a recent history of myocardial infarction or unstable cardiovascular disease. Such patients were 
> excluded from the premarketing clinical studies.”

Source: [REXULTI: Prescribing information, page 13, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=13)

<a id="rexulti-drowsiness-driving"></a>

### Can Rexulti cause drowsiness or affect driving?

> “REXULTI, like other antipsychotics, may cause somnolence and has the potential to impair judgment, thinking, 
> or motor skills. In the 6-week placebo-controlled clinical studies in patients with MDD, somnolence (including 
> sedation and hypersomnia) was reported in 4% of REXULTI plus ADT-treated patients compared to 1% of 
> placebo plus ADT-treated patients.”

Source: [REXULTI: Prescribing information, page 13, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=13)

> “Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are 
> reasonably certain that REXULTI therapy does not affect them adversely.”

Source: [REXULTI: Prescribing information, page 14, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=14)

## Side effects

<a id="rexulti-side-effects"></a>

### What are the most common side effects of Rexulti for depression?

> “The most common adverse reactions (≥5%) and at least twice the rate of placebo for ADT + REXULTI vs ADT + placebo were weight increased (7% vs 2%), somnolence (5% vs 0.5%), and akathisia (9% vs 2%)”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Safety, captured 2026-11-13](https://www.rexultihcp.com/mdd/safety#:~:text=The%20most%20common%20adverse%20reactions,and%20akathisia%20%289%25%20vs%202%25%29)

> “Adverse reactions associated with the adjunctive use of REXULTI (incidence of 2% or greater and adjunctive 
> REXULTI incidence greater than adjunctive placebo) that occurred during acute therapy (up to 6-weeks in 
> patients with MDD) are shown in Table 8. 
> Table 8 
> Adverse Reactions in ≥2% of REXULTI-Treated Patients and Greater than Placebo in 
> Pooled 6-Week Placebo-Controlled, Fixed-Dose Adjunctive MDD Studies in Adults (Study 1 
> and Study 2) 
>
> Placebo 
> (N=411) 
> % 
> REXULTI 
> 1 mg/day 
> (N=226) 
> % 
> 2 mg/day 
> (N=188) 
> % 
> 3 mg/day 
> (N=229) 
> % 
> All 
> REXULTI 
> (N=643) 
> % 
> Gastrointestinal Disorders 
> Constipation 
> 1 
> 3 
> 2 
> 1 
> 2 
> General Disorders and Administration Site Conditions 
> Fatigue 
> 2 
> 3 
> 2 
> 5 
> 3 
> Infections and Infestations 
> Nasopharyngitis 
> 2 
> 7 
> 1 
> 3 
> 4 
> Investigations 
> Weight Increased 
> 2 
> 7 
> 8 
> 6 
> 7 
> Blood Cortisol Decreased 
> 1 
> 4 
> 0 
> 3 
> 2 
> Metabolism and Nutrition 
> Increased Appetite 
> 2 
> 3 
> 3 
> 2 
> 3 
> Nervous System Disorders 
> Akathisia 
> 2 
> 4 
> 7 
> 14 
> 9 
> Headache 
> 6 
> 9 
> 4 
> 6 
> 7 
> Somnolence 
> 0.5 
> 4 
> 4 
> 6 
> 5 
> Tremor 
> 2 
> 4 
> 2 
> 5 
> 4 
> Dizziness 
> 1 
> 1 
> 5 
> 2 
> 3 
> Psychiatric Disorders 
> Anxiety 
> 1 
> 2 
> 4 
> 4 
> 3”

Source: [REXULTI: Prescribing information, page 15, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=15)

> “Restlessness 
> 0 
> 2 
> 3 
> 4 
> 3”

Source: [REXULTI: Prescribing information, page 16, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=16)

Note: Table 8 columns are placebo, REXULTI 1 mg/day, 2 mg/day, 3 mg/day, and all REXULTI, in that order (% of patients); the table continues on the next page with restlessness.

<a id="rexulti-discontinuation-side-effects"></a>

### How many patients stopped Rexulti for side effects in depression trials?

> “The safety of REXULTI was evaluated in 1054 adult patients (18 to 65 years of age) diagnosed with MDD who 
> participated in two 6-week placebo-controlled, fixed-dose clinical studies in patients with major depressive 
> disorder in which REXULTI was administered at doses of 1 mg to 3 mg daily as adjunctive treatment to 
> continued antidepressant therapy; patients in the placebo group continued to receive antidepressant therapy 
> [see Clinical Studies (14.1)].”

Source: [REXULTI: Prescribing information, page 15, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=15)

> “A total of 3% (17/643) of REXULTI-treated patients and 1% (3/411) of placebo-treated patients discontinued 
> due to adverse reactions.”

Source: [REXULTI: Prescribing information, page 15, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=15)

> “In patients taking ADT + REXULTI (n=643, all doses) vs ADT + placebo (n=411), the rate of discontinuation due to akathisia was 0.9% vs 0% and the rate of discontinuation due to weight gain was 0% vs 0%, respectively<sup>3,4</sup>”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Safety, captured 2026-11-13](https://www.rexultihcp.com/mdd/safety#:~:text=across%20all%20doses-,In%20patients%20taking%20ADT%20%2B%20REXULTI%20%28n%3D643%2C%20all%20doses%29%20vs,gain%20was%200%25%20vs%200%25%2C)

Note: Figures are from the two 6-week placebo-controlled adjunctive MDD studies (Studies 1 and 2).

<a id="rexulti-akathisia"></a>

### Does Rexulti cause akathisia or restlessness in depression trials?

> “The incidence of reported extrapyramidal symptoms (EPS)-related adverse reactions, excluding akathisia, was 
> 6% for REXULTI plus ADT-treated patients versus 3% for placebo plus ADT-treated patients. The incidence of 
> akathisia events for REXULTI plus ADT-treated patients was 9% versus 2% for placebo plus ADT-treated 
> patients.  
> In the 6-week placebo-controlled MDD studies, data was objectively collected on the Simpson-Angus Rating 
> Scale (SAS) for EPS, the Barnes Akathisia Rating Scale (BARS) for akathisia and the Abnormal Involuntary 
> Movement Score (AIMS) for dyskinesia. The mean change from baseline at last visit for REXULTI plus ADT-
> treated patients for the SAS, BARS and AIMS was comparable to placebo-treated patients. The percentage of 
> patients who shifted from normal to abnormal was greater in REXULTI plus ADT-treated patients versus 
> placebo plus ADT-treated patients for the BARS (4% versus 0.6%) and the SAS (4% versus 3%).”

Source: [REXULTI: Prescribing information, page 18, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=18)

> “In Studies 1 and 2, among the adverse reactions that occurred at ≥2% incidence in the patients treated with 
> REXULTI plus ADT, the incidences of akathisia and restlessness increased with increases in dose.”

Source: [REXULTI: Prescribing information, page 16, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=16)

> “A majority of the akathisia cases reported were mild or moderate<sup>14</sup>”

Source: [REXULTI: BROCHURE, page 9, captured 2026-11-13](https://www.rexultihcp.com/mdd/content/dam/rexulti/hcp/websites/com/live-assets/pdfs/documents/11us25ebp0380rexultimddunmetneedleavebehinddigital.pdf#page=9)

Note: The last passage is from the MDD leave-behind that the resources page of the Rexulti HCP site links; it cites a 2015 conference poster analyzing Studies 1 and 2 (Weiss et al., ASCP 2015).

<a id="rexulti-weight-gain"></a>

### How much weight gain does Rexulti cause in depression trials?

> “Adjunctive Treatment of Major Depressive Disorder: Table 6 shows weight gain data at last visit and 
> percentage of adult patients with ≥7% increase in body weight at endpoint from the 6-week placebo-controlled, 
> fixed-dose clinical studies in patients with MDD. 
> Table 6 
> Increases in Body Weight in the 6-Week Placebo-Controlled, Fixed-Dose MDD Studies 
>
> Placebo 
> 1 mg/day 
> 2 mg/day 
> 3 mg/day 
>
> n=407 
> n=225 
> n=187 
> n=228”

Source: [REXULTI: Prescribing information, page 10, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=10)

> “Table 6 
> Increases in Body Weight in the 6-Week Placebo-Controlled, Fixed-Dose MDD Studies 
> Mean Change from Baseline (kg) at Last Visit 
> All Patients 
> +0.3 
> +1.3 
> +1.6 
> +1.6 
> Proportion of Patients with a ≥7% Increase in Body Weight (kg) at Any Visit (n/N*) 
>
> 2% 
> 5% 
> 5% 
> 2% 
>
> (8/407)* 
> (11/225)* 
> (9/187)* 
> (5/228)* 
> *N=the total number of patients who had a measurement at baseline and at least one post-baseline result; n=the number of patients 
> with a shift ≥7%”

Source: [REXULTI: Prescribing information, page 11, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=11)

Note: Table 6 columns are placebo, REXULTI 1 mg/day, 2 mg/day, and 3 mg/day, in that order; the table begins on one page and continues on the next.

<a id="rexulti-long-term-side-effects"></a>

### What are the long-term side effects of Rexulti (52-week depression studies)?

> “In the long-term, open-label depression studies, 4% of patients discontinued due to weight increase. REXULTI 
> was associated with mean change from baseline in weight of 2.9 kg at Week 26 and 3.1 kg at Week 52. In the 
> long-term, open-label depression studies, 30% of patients demonstrated a ≥7% increase in body weight, and 
> 4% demonstrated a ≥7% decrease in body weight.”

Source: [REXULTI: Prescribing information, page 11, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=11)

> “In the long-term, open-label 
> depression studies, 5% of adult patients with normal baseline fasting glucose experienced a shift to high while 
> taking REXULTI plus an antidepressant (ADT); 25% of patients with borderline fasting glucose experienced 
> shifts to high. Combined, 9% of patients with normal or borderline fasting glucose experienced shifts to high 
> fasting glucose during the long-term depression studies.”

Source: [REXULTI: Prescribing information, page 8, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=8)

> “In the long-term, open-label depression studies, shifts in baseline fasting cholesterol from normal to high were 
> reported in 9% (total cholesterol), 3% (LDL cholesterol), and shifts in baseline from normal to low were 
> reported in 14% (HDL cholesterol) of patients taking REXULTI. Of patients with normal baseline triglycerides, 
> 17% experienced shifts to high, and 0.2% experienced shifts to very high. Combined, 0.6% of patients with 
> normal or borderline fasting triglycerides experienced shifts to very high fasting triglycerides during the long-
> term depression studies.”

Source: [REXULTI: Prescribing information, page 9, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=9)

> “After the conclusion of the 6-week trials, patients who elected to remain in a trial, patients from Phase 2 trials, and de novo patients were treated with flexible doses of antidepressants + REXULTI in a 52-week, open-label trial, where no placebo control was included
> Safety data were collected at regular intervals throughout the 52-week, open-label trial”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Safety, captured 2026-11-13](https://www.rexultihcp.com/mdd/safety#:~:text=After%20the%20conclusion%20of%20the,throughout%20the%2052%2Dweek%2C%20open%2Dlabel%20trial)

Note: The open-label depression studies had no placebo control.

<a id="rexulti-decreased-libido"></a>

### Does Rexulti cause sexual side effects such as decreased libido?

> “In patients taking ADT + REXULTI (n=643, all doses) vs ADT + placebo (n=411), the incidence of decreased libido was 0.6% vs 0.2%, respectively<sup>1</sup>”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Safety, captured 2026-11-13](https://www.rexultihcp.com/mdd/safety#:~:text=In%20patients%20taking%20ADT%20%2B,libido%20was%200.6%25%20vs%200.2%25%2C)

Note: Rates are from the two 6-week placebo-controlled adjunctive MDD studies, as reported on the safety page of the Rexulti HCP site, which cites data on file.

## Related pages
- [Medical information: Rexulti (brexpiprazole): Major depressive disorder](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder)
- [Indication](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/access-and-coverage)
